AbbVievsSpero Therapeutics

ABBV and SPRO stock compared: price, dividend, valuation and results, from SEC filings.

SPRO

Spero Therapeutics, Inc.

$1.00

Value $58M

+0.00%
SPRO's page

AbbVie (ABBV) has a market value of $522B and Spero Therapeutics (SPRO) $58M. Over the last year, with dividends, ABBV moved +30.3% and SPRO -62.4%. Dividend yield: ABBV 2.35%, SPRO none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABBV$522B

    SPRO$58M

    ABBV is 9,012 times SPRO

  • Revenue, 12 months

    ABBV$66.0B

    SPRO$42M

    ABBV is 1,589 times SPRO

  • Net income, 12 months

    ABBV$10.3B

    SPRO-$30M

  • Operating margin

    ABBV32.2%

    SPRO-67.3%

    99.5 points apart

  • ROIC

    ABBV25.7%

    SPRO-60.2%

    85.9 points apart

  • P/E

    ABBV50.7

    SPRO–

  • Dividend yield

    ABBV2.4%

    SPRO0.0%

    2.4 points apart

  • 5-year return

    ABBV+201.5%

    SPRO-94.0%

    295.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABBV+201.5%

SPRO-94.0%

010020030020222023202420252026
Returns by period
PeriodABBVWith dividendsSPROWith dividends
1 year since November 12, 2025+30.3%Price +26.5%-62.4%Price -62.4%
3 years since November 13, 2023+135.3%+33.0% a yearPrice +112.8%-9.9%-3.4% a yearPrice -9.9%
5 years since November 12, 2021+201.5%+24.7% a yearPrice +152.2%-94.0%-43.1% a yearPrice -94.0%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABBVAbbVieSPROSpero Therapeutics

Valuation

ABBVSPRO
Valuation
Price$295.03$1.00
Market value$522B$58M
Enterprise value (EV)$592B–
P/E50.7–
P/E, 5-year median57.0–
P/B–74.1
EV/EBIT27.9–
Free cash flow yield3.6%–

Results and growth

ABBVSPRO
Results and growth
Revenue, 12 months$66.0B$42M
Net income, 12 months$10.3B-$30M
Free cash flow, 12 months$18.9B-$40M
Earnings per share, 12 months$5.81-$0.49
Revenue growth, year on year8.6%39.2%
Revenue growth a year, past+5.9%over 5 years+48.3%over 5 years
EPS growth a year, past-2.8%over 5 years–

Margins and returns on capital

ABBVSPRO
Margins and returns on capital
Gross margin73.7%–
Operating margin32.2%-67.3%
Net margin15.7%-71.0%
ROIC25.7%-60.2%
ROE–-80.5%

Balance sheet

ABBVSPRO
Balance sheet
Cash$10.8B$108M
Total debt$80.9B$1.6M
Net debt / EBITDA3.2–
Interest cover7.1×–

Dividends and buybacks

ABBVSPRO
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$6.92–
Dividend growth a year, past+6.6%over 5 years–
Buyback yield0.2%–
Shareholder yield2.5%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABBV or SPRO

Didn't find what you were looking for?

Ask us
Which is bigger, AbbVie or Spero Therapeutics?

By market value, AbbVie ($522B) is about 9,011.9 times Spero Therapeutics ($58M), at today's prices.

How did ABBV and SPRO stock do over the last 5 years?

Since November 12, 2021, ABBV's price moved +152.2% and SPRO's -94.0%. With dividends: ABBV +201.5% (+24.7% a year), SPRO -94.0% (-43.1% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABBV or SPRO?

The dividend yield at today's price is 2.35% for AbbVie and none for Spero Therapeutics. Over the last twelve months they paid $6.92 and – per share.

Which has the higher profit margins, AbbVie or Spero Therapeutics?

Over the last twelve months, the net margin was 15.7% for AbbVie and -71.0% for Spero Therapeutics, and the operating margin 32.2% and -67.3%. Revenue was $66.0B and $42M.

Which is the better investment, AbbVie or Spero Therapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.